Cerebellar glioblastoma in adults: a comparative single-center matched pair analysis and systematic review of the literature.
Cerebellar glioblastoma
Matched pair analysis
Overall survival
Propensity score matching
Supratentorial glioblastoma
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
16
06
2024
accepted:
17
09
2024
medline:
29
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
The rarity of cerebellar glioblastoma presents a significant challenge in clinical practice due to the lack of extensive prognostic data on long-term survival rates, rendering it an underrepresented entity compared to its supratentorial counterpart. This study aims to analyze potential differences in survival outcome between patients with cerebellar and supratentorial glioblastomas. From 2009 to 2020, 8 patients underwent surgical treatment for cerebellar glioblastoma at the authors' institution. These patients were individually matched with a cohort of 205 consecutive patients from our institutional database with supratentorial glioblastoma, taking into account key prognostic parameters. Progression-free survival (PFS) and overall survival (OS) rates were compared. Additionally, we performed a systematic literature review to compile further survival data on cerebellar glioblastoma patients. The median OS for cerebellar glioblastoma patients was 18 months (95% CI 11-25). The balanced matched-pair analysis showed no significant difference in survival when compared to patients with supratentorial glioblastoma, exhibiting a median OS of 23 months (95% CI 0-62) (p = 0.63). Respective values for PFS were 8 months (95% CI 4-12) for cerebellar and 7 months (95% CI 0-16) for supratentorial glioblastoma (p = 0.2). The systematic review revealed that median OS for cerebellar glioblastoma in current literature ranges from 7 to 21 months. The present findings indicate that patients with supra- and infratentorial glioblastoma do not significantly differ in regard to survival outcome parameters. This similarity in prognosis might encourage clinicians to consider surgical interventions for both supra- and infratentorial glioblastoma in a similar manner.
Identifiants
pubmed: 39340649
doi: 10.1007/s00432-024-05959-0
pii: 10.1007/s00432-024-05959-0
doi:
Types de publication
Journal Article
Systematic Review
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
432Informations de copyright
© 2024. The Author(s).
Références
Adams H, Chaichana KL, Avendaño J et al (2013) Adult Cerebellar Glioblastoma: understanding survival and prognostic factors using a Population-based database from 1973 to 2009. World Neurosurg 80:e237–e243. https://doi.org/10.1016/j.wneu.2013.02.010
doi: 10.1016/j.wneu.2013.02.010
pubmed: 23395851
pmcid: 3994535
Babu R, Sharma R, Karikari IO et al (2013) Outcome and prognostic factors in adult cerebellar glioblastoma. J Clin Neurosci 20:1117–1121. https://doi.org/10.1016/j.jocn.2012.12.006
doi: 10.1016/j.jocn.2012.12.006
pubmed: 23706183
Borger V, Hamed M, Ilic I et al (2021) Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection. J Neurooncol 152:339–346. https://doi.org/10.1007/s11060-021-03705-x
doi: 10.1007/s11060-021-03705-x
pubmed: 33554293
pmcid: 7997820
Chandra A, Lopez-Rivera V, Dono A et al (2021) Comparative Analysis of Survival Outcomes and prognostic factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: does location really Matter? World Neurosurg 146:e755–e767. https://doi.org/10.1016/j.wneu.2020.11.003
doi: 10.1016/j.wneu.2020.11.003
pubmed: 33171326
Cho HJ, Zhao J, Jung SW et al (2019) Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. 21:47–58. https://doi.org/10.1093/neuonc/noy123
Dejonckheere CS, Layer JP, Hamed M et al (2023) Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes. J Neurooncol 164:683–691. https://doi.org/10.1007/s11060-023-04464-7
doi: 10.1007/s11060-023-04464-7
pubmed: 37812290
pmcid: 10589145
Dubey A, Sung W-S, Shaya M et al (2009) Complications of posterior cranial fossa surgery—an institutional experience of 500 patients. Surg Neurol 72:369–375. https://doi.org/10.1016/j.surneu.2009.04.001
doi: 10.1016/j.surneu.2009.04.001
pubmed: 19604553
Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A Randomized Trial of Bevacizumab for newly diagnosed Glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573
doi: 10.1056/NEJMoa1308573
pubmed: 24552317
pmcid: 4201043
Gomes CA, Steiner KM, Ludolph N et al (2021) Resection of cerebellar tumours causes widespread and functionally relevant white matter impairments. Hum Brain Mapp 42:1641–1656. https://doi.org/10.1002/hbm.25317
doi: 10.1002/hbm.25317
pubmed: 33410575
pmcid: 7978119
Gopalakrishnan CV, Dhakoji A, Nair S et al (2012) A retrospective study of primary cerebellar glioblastoma multiforme in adults. J Clin Neurosci 19:1684–1688. https://doi.org/10.1016/j.jocn.2011.12.035
doi: 10.1016/j.jocn.2011.12.035
pubmed: 23084346
Hamed M, Potthoff A-L, Layer JP et al (2022) Benchmarking Safety indicators of Surgical Treatment of Brain metastases combined with intraoperative Radiotherapy: results of prospective observational study with comparative matched-pair analysis. Cancers 14:1515. https://doi.org/10.3390/cancers14061515
doi: 10.3390/cancers14061515
pubmed: 35326666
pmcid: 8946541
Hamed M, Potthoff A-L, Heimann M et al (2023) Survival in patients with surgically treated brain metastases: does infratentorial location matter? Neurosurg Rev 46. https://doi.org/10.1007/s10143-023-01986-6
Herrlinger U, Tzaridis T, Mack F et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet 393:678–688. https://doi.org/10.1016/S0140-6736(18)31791-4
doi: 10.1016/S0140-6736(18)31791-4
pubmed: 30782343
Hong B, Banan R, Christians A et al (2018) Cerebellar glioblastoma: a clinical series with contemporary molecular analysis. Acta Neurochir 160:2237–2248. https://doi.org/10.1007/s00701-018-3673-y
doi: 10.1007/s00701-018-3673-y
pubmed: 30203362
Jeswani S, Nuño M, Folkerts V et al (2013) Comparison of Survival between Cerebellar and Supratentorial Glioblastoma patients. 73:240–246. https://doi.org/10.1227/01.neu.0000430288.85680.37
Kane LT, Fang T, Galetta MS et al (2020) Propensity Score Matching 33:120–122. https://doi.org/10.1097/BSD.0000000000000932
doi: 10.1097/BSD.0000000000000932
Kreth F-W, Thon N, Simon M et al (2013) Gross total but not incomplete resection of Glioblastoma prolongs survival in the era of radiochemotherapy. Ann Oncol 24:3117–3123. https://doi.org/10.1093/annonc/mdt388
doi: 10.1093/annonc/mdt388
pubmed: 24130262
Layer JP, Hamed M, Potthoff A-L et al (2023) Outcome assessment of intraoperative radiotherapy for brain metastases: results of a prospective observational study with comparative matched-pair analysis. J Neurooncol 164:107–116. https://doi.org/10.1007/s11060-023-04380-w
doi: 10.1007/s11060-023-04380-w
pubmed: 37477822
pmcid: 10462513
Levine SA, McKeever PE, Greenberg HS (1987) Primary cerebellar glioblastoma multiforme. J Neuro-Oncol 5:231–236. https://doi.org/10.1007/BF00151226
doi: 10.1007/BF00151226
Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? JNS 124:977–988. https://doi.org/10.3171/2015.5.JNS142087
doi: 10.3171/2015.5.JNS142087
McGirt MJ, Chaichana KL, Gathinji M et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. JNS 110:156–162. https://doi.org/10.3171/2008.4.17536
doi: 10.3171/2008.4.17536
Mikeska T, Bock C, El-Maarri O et al (2007) Optimization of Quantitative MGMT promoter methylation analysis using pyrosequencing and combined Bisulfite Restriction Analysis. J Mol Diagn 9:368–381. https://doi.org/10.2353/jmoldx.2007.060167
doi: 10.2353/jmoldx.2007.060167
pubmed: 17591937
pmcid: 1899414
Milinkovic VP, Skender Gazibara MK, Manojlovic Gacic EM et al (2014) The impact of TP53 and RAS mutations on cerebellar glioblastomas. Exp Mol Pathol 97:202–207. https://doi.org/10.1016/j.yexmp.2014.07.009
doi: 10.1016/j.yexmp.2014.07.009
pubmed: 25036404
Ostrom QT, Patil N, Cioffi G et al (2020) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. 22:iv1–iv96. https://doi.org/10.1093/neuonc/noaa200
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. https://doi.org/10.1136/bmj.n71 . BMJ n71
Picart T, Barritault M, Berthillier J et al (2018) Characteristics of cerebellar glioblastomas in adults. J Neurooncol 136:555–563. https://doi.org/10.1007/s11060-017-2682-7
doi: 10.1007/s11060-017-2682-7
pubmed: 29196927
Potthoff A-L, Heiland DH, Evert BO et al (2019) Inhibition of gap junctions sensitizes primary glioblastoma cells for Temozolomide. Cancers 11:858. https://doi.org/10.3390/cancers11060858
doi: 10.3390/cancers11060858
pubmed: 31226836
pmcid: 6628126
Radke J, Koch A, Pritsch F et al (2019) Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. https://doi.org/10.1186/s40478-019-0745-z . acta neuropathol commun 7:
Reinhardt A, Stichel D, Schrimpf D et al (2019) Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. https://doi.org/10.1186/s40478-019-0801-8 . acta neuropathol commun 7:
Schäfer N, Bumes E, Eberle F et al (2021) Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. J Neurooncol 153:479–485. https://doi.org/10.1007/s11060-021-03784-w
doi: 10.1007/s11060-021-03784-w
pubmed: 34115248
pmcid: 8192684
Schneider M, Güresir Á, Borger V et al (2019a) Preoperative tumor-associated epilepsy in patients with supratentorial meningioma: factors influencing seizure outcome after meningioma surgery. 1–7. https://doi.org/10.3171/2019.7.JNS19455
Schneider M, Potthoff A-L, Keil VC et al (2019b) Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. J Neurooncol 145:143–150. https://doi.org/10.1007/s11060-019-03281-1
doi: 10.1007/s11060-019-03281-1
pubmed: 31485921
Schneider M, Ilic I, Potthoff A-L et al (2020a) Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates. J Neurooncol 149:455–461. https://doi.org/10.1007/s11060-020-03629-y
doi: 10.1007/s11060-020-03629-y
pubmed: 32990861
pmcid: 7609430
Schneider M, Potthoff A-L, Scharnböck E et al (2020b) Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. J Neurooncol 149:421–427. https://doi.org/10.1007/s11060-020-03625-2
doi: 10.1007/s11060-020-03625-2
pubmed: 32989681
pmcid: 7609438
Schneider M, Borger V, Grigutsch D et al (2021) Elevated body mass index facilitates early postoperative complications after surgery for intracranial meningioma. Neurosurg Rev 44:1023–1029. https://doi.org/10.1007/s10143-020-01281-8
doi: 10.1007/s10143-020-01281-8
pubmed: 32212047
Schulte JD, Buerki RA, Lapointe S et al (2020) Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. 2. https://doi.org/10.1093/noajnl/vdaa142
Shonka NA, Aizenberg MR (2017) Extent of Resection in Glioblastoma. JOP 13:641–642. https://doi.org/10.1200/JOP.2017.027599
doi: 10.1200/JOP.2017.027599
pubmed: 29020534
Simpson JR, Horton J, Scott C et al (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive radiation therapy oncology group (RTOG) clinical trials. Int J Radiation Oncology*Biology*Physics 26:239–244. https://doi.org/10.1016/0360-3016(93)90203-8
doi: 10.1016/0360-3016(93)90203-8
Smrdel U, Popovic M, Zwitter M et al (2016) Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. 50:394–401. https://doi.org/10.1515/raon-2015-0041
Stupp R, Mason WP, van den Bent MJ et al (2005a) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Stupp R, Mason WP, van den Bent MJ et al (2005b) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
Takahashi Y, Makino K, Nakamura H et al (2014) Clinical characteristics and pathogenesis of cerebellar glioblastoma. 10:2383–2388. https://doi.org/10.3892/mmr.2014.2549
Thomas TP, Gopalakrishna R, Anderson WB (1987) Hormone- and tumor promoter-induced activation or membrane association of protein kinase C in intact cells. 399–411. https://doi.org/10.1016/0076-6879(87)41086-0
Tsung AJ, Prabhu SS, Lei X et al (2011) Cerebellar glioblastoma: a retrospective review of 21 patients at a single institution. J Neurooncol 105:555–562. https://doi.org/10.1007/s11060-011-0617-2
doi: 10.1007/s11060-011-0617-2
pubmed: 21643841
Utsuki S, Oka H, Miyajima Y et al (2012) Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma. Brain Tumor Pathol 29:87–95. https://doi.org/10.1007/s10014-011-0070-0
doi: 10.1007/s10014-011-0070-0
pubmed: 22076316
Venkataramani V, Schneider M, Giordano FA et al (2022) Disconnecting multicellular networks in brain tumours. Nat Rev Cancer 22:481–491. https://doi.org/10.1038/s41568-022-00475-0
doi: 10.1038/s41568-022-00475-0
pubmed: 35488036
Weber DC, Miller RC, Villà S et al (2006) Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network. Int J Radiation Oncology*Biology*Physics 66:179–186. https://doi.org/10.1016/j.ijrobp.2006.04.035
doi: 10.1016/j.ijrobp.2006.04.035
Yan H, Parsons DW, Jin G et al (2009) IDH1andIDH2Mutations in Gliomas. N Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710
doi: 10.1056/NEJMoa0808710
pubmed: 19228619
pmcid: 2820383
Zeyen T, Paech D, Weller J et al (2023) Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. J Neurooncol 164:607–616. https://doi.org/10.1007/s11060-023-04444-x
doi: 10.1007/s11060-023-04444-x
pubmed: 37728779
pmcid: 10589172
Zhang M, Li R, Pollom EL et al (2020) Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: a National Cancer database study. J Clin Neurosci 82:122–127. https://doi.org/10.1016/j.jocn.2020.10.049
doi: 10.1016/j.jocn.2020.10.049
pubmed: 33317719
pmcid: 7738760
Zhou J, Shi L-F, Wang Z et al (2023) OLIG2 expression level could be used as an independent prognostic factor for patients with cerebellar Glioblastoma (cGBM). Clinics 78:100120. https://doi.org/10.1016/j.clinsp.2022.100120
doi: 10.1016/j.clinsp.2022.100120
pubmed: 37001387
pmcid: 10126729